Please login to the form below

Not currently logged in
Email:
Password:

lacosamide

This page shows the latest lacosamide news and features for those working in and with pharma, biotech and healthcare.

Tecentriq’s triple negative breast cancer use among key CHMP nods

Tecentriq’s triple negative breast cancer use among key CHMP nods

UCB’s Vimpat (lacosamide) also gained a thumbs up in the epilepsy market, with a recommendation in partial-onset seizures with or without secondary generalisation.

Latest news

More from news
Approximately 4 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • VIDEO interview: Neil Weir, UCB VIDEO interview: Neil Weir, UCB

    For UCB, this notion is especially important considering its focus on severe diseases, including the recent launches of Cimzia (certolizumab pegol) for rheumatoid arthritis and Crohn's disease; Vimpat (lacosamide) for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...